Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Total Valuation
Abeona Therapeutics has a market cap or net worth of $241.15M. The enterprise value is $103.05M.
Market Cap$241.15M
Enterprise Value$103.05M
Share Statistics
Abeona Therapeutics has 54,191,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,191,360
Owned by Insiders5.63%
Owned by Institutions43.07%
Financial Efficiency
Abeona Therapeutics’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -64.80%.
Return on Equity (ROE)-1.45
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-64.80%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee0.00
Profits Per Employee-468.63K
Employee Count136
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Abeona Therapeutics is 3.8. Abeona Therapeutics’s PEG ratio is 0.09.
PE Ratio3.8
PS Ratio0.00
PB Ratio5.19
Price to Fair Value5.19
Price to FCF-3.91
Price to Operating Cash Flow-3.19
PEG Ratio0.09
Income Statement
In the last 12 months, Abeona Therapeutics had revenue of 0.00 and earned -63.73M in profits. Earnings per share was -1.55.
Revenue0.00
Gross Profit-2.91M
Operating Income-64.21M
Pretax Income-63.73M
Net Income-63.73M
EBITDA-56.62M
Earnings Per Share (EPS)-1.55
Cash Flow
In the last 12 months, operating cash flow was -74.93M and capital expenditures -7.43M, giving a free cash flow of -82.36M billion.
Operating Cash Flow-74.93M
Free Cash Flow-82.36M
Free Cash Flow per Share-1.52
Dividends & Yields
Abeona Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.78
52-Week Price Change-24.06%
50-Day Moving Average5.34
200-Day Moving Average5.74
Relative Strength Index (RSI)39.72
Average Volume (3m)2.11M
Important Dates
Abeona Therapeutics upcoming earnings date is Mar 23, 2026, TBA (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 23, 2026
Ex-Dividend Date―
Financial Position
Abeona Therapeutics as a current ratio of 6.08, with Debt / Equity ratio of 14.08%
Current Ratio6.08
Quick Ratio6.08
Debt to Market Cap0.08
Net Debt to EBITDA<0.01
Interest Coverage Ratio-15.26
Taxes
In the past 12 months, Abeona Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Abeona Therapeutics EV to EBITDA ratio is -4.03, with an EV/FCF ratio of -3.91.
EV to Sales0.00
EV to EBITDA-4.03
EV to Free Cash Flow-3.91
EV to Operating Cash Flow-4.08
Balance Sheet
Abeona Therapeutics has $207.46M in cash and marketable securities with $24.11M in debt, giving a net cash position of $183.35M billion.
Cash & Marketable Securities$207.46M
Total Debt$24.11M
Net Cash$183.35M
Net Cash Per Share$3.38
Tangible Book Value Per Share$1.07
Margins
Gross margin is 26.79%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin26.79%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Abeona Therapeutics is $22.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.17
Price Target Upside398.20% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―